Eli Lilly: capacity is the constraint, not demand
Demand for the weight-loss drugs exceeds what the company can make, and it has been that way for two years. Every new plant that comes online converts waiting patients into revenue. The multiple is high; the earnings growth behind it is higher.
Read research →